Scilex Holding Announces Publication Of Trial Results For SP-102 (SEMDEXA) In PAIN Journal; Focuses On Non-Opioid Pain Management Products For Acute And Chronic Pain
Portfolio Pulse from Benzinga Newsdesk
Scilex Holding announced the publication of Phase 3 trial results for SP-102 (SEMDEXA) in the PAIN Journal. The study showed significant pain reduction and improved disability index scores in sciatica patients, with safety comparable to placebo. SP-102 has Fast Track status from the FDA.
June 14, 2024 | 5:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scilex Holding's Phase 3 trial results for SP-102 (SEMDEXA) published in PAIN Journal show significant pain reduction and improved disability scores in sciatica patients. This could positively impact the stock price.
The publication of positive Phase 3 trial results in a leading journal and the demonstrated efficacy and safety of SP-102 (SEMDEXA) are likely to boost investor confidence and positively impact Scilex Holding's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100